<DOC>
	<DOCNO>NCT02108522</DOCNO>
	<brief_summary>Patients enrol study receive stem cell transplant . After transplant , immune system grow back patient risk infection . Some virus stay body life immune system weaken , like transplant , cause life threaten infection . Patients enrol study infection one following viruses - Epstein Barr virus ( EBV ) , cytomegalovirus ( CMV ) , BK virus , JC virus , adenovirus HHV6 ( Human Herpes Virus 6 ) . Investigators want see use kind white blood cell call T cell treat infection virus transplant . Investigators observe study treatment specially trained T cell successful cell make transplant donor . However take 1-2 month make cell , approach practical patient already infection . Investigators generate multivirus-specific T cell ( VSTs ) blood healthy donor create bank cell . Investigators previously successfully use frozen multivirus-specific T cell healthy donor treat virus infection bone marrow transplant improve production method make safe target virus . In study , investigator want find use bank VSTs fight infection cause virus mention .</brief_summary>
	<brief_title>Multivirus-specific T Cells Treatment Virus Infections After Stem Cell Transplant</brief_title>
	<detailed_description>These VST line make Baylor College Medicine donor transplant patient normal donor National Marrow Donor Program . All donor screen standard blood bank donor questionnaire , medical history test infectious disease doctor experience screen transplant donor . Only donor clear process deem eligible provide blood VST generation . The line make use special process . To make VSTs investigator mix donor cell small piece protein , call peptide come adenovirus , CMV , EBV , BKV HHV6 . These peptide stimulate donor T cell react virus grow train donor T cell kill cell infect CMV , EBV , adenovirus , BKV HHV6 . Once investigator make sufficient number VSTs , test make sure would target cell infected virusesbut normal cell . Then cell freeze . For patient treat study , VSTs thaw inject intravenous line . The patient remain clinic least one hour infusion . After patient receives cell , transplant doctor monitor level virus patient infect blood . The investigator also take blood see long VSTs give patient last body . The patient continue follow doctor injection . The patient either see clinic contact research nurse follow study every week 6 week 3 , 6 12 month . The patient may visit standard care . The patient also regular blood test do follow count viral infection , do part standard medical care . To learn way VSTs work patient 's body , extra 30-40 ml ( 6-8 teaspoon ) blood take infusion 1 , 2 , 3 , 4 , 6 week 3 month . Blood come central intravenous line , require extra needle stick . All participant study infused number ( dose ) cell . If first treatment patient persistent infection , would discuss him/her allow option receive treatment . These additional treatment might cell donor feel another donor 's whose cell might better patient , would use cell different donor . This second product administer dose level 28 day initial infusion , subsequent infusion least 14 day apart . After VST infusion , patient monitor described .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>For Initial VSTs subsequent infusion : patient eligible follow type allogeneic transplant CMV , adenovirus , EBV , BK virus and/or HHV6 infection/disease persistent recurrent despite 14 day standard therapy OR failure treatment 7 day standard therapy OR unable tolerate standard therapy . Patients persistent JC virus infection eligible well . 1 . Prior myeloablative nonmyeloablative allogeneic hematopoietic stem cell transplant use either bone marrow peripheral blood stem cell single double cord blood . 2 . Treatment follow persistent relapse infection despite standard therapy ; 1 . CMV : Treatment persistent relapse CMV disease infection standard therapy . For CMV infection , standard therapy define antiviral therapy ganciclovir , foscarnet cidofovir . CMV disease : define demonstration CMV biopsy specimen visceral site ( culture histology ) detection CMV culture direct fluorescent antibody stain broncheoalveolar lavage fluid presence new change pulmonary infiltrates change consistent CMV retinitis ophthalmologic examination . CMV infection : define presence CMV positivity detect PCR pp65 antigenemia culture ONE site stool blood urine nasopharynx . Failure antiviral therapy : define rise fall le 50 % viral load peripheral blood site disease measure PCR pp65 antigenemia 7 day antiviral therapy . 2 . Adenovirus : Treatment persistent adenovirus infection disease despite standard therapy . Standard therapy define antiviral therapy cidofovir alternative antiviral agent patient tolerate cidofovir therapy poor renal function . Adenovirus infection : define presence adenoviral positivity detect PCR culture ONE site stool blood urine nasopharynx . Adenovirus disease : define presence adenoviral positivity detect PCR , DFA culture two site stool blood urine nasopharynx . Failure therapy : define rise fall le 50 % viral load peripheral blood site disease measure PCR quantitative assay ) 7 day antiviral therapy . 3 . EBV : For treatment persistent EBV infection despite standard therapy . For EBV infection , standard therapy define rituximab give 375mg/m2 patient 14 dos CD20+ve tumor . EBV infection : define Biopsy proven lymphoma EBV genome detect tumor cell immunocytochemistry situ PCR , Or clinical imaging finding consistent EBV lymphoma and/or elevate EBV viral load peripheral blood . Failure therapy define : Increase le 50 % response sit disease EBV lymphoma OR , Increase fall le 50 % EBV viral load peripheral blood site disease 1st dose rituximab . 4 . BK virus : Treatment persistent BK virus infection BK virus disease despite antiviral treatment cidofovir leflunomide . No clear standard treatment define . Cidofovir administer low dos well high dos HSCT patient BK infection randomize trial available prove clinical efficacy . In small trial leflunomide activity BK virus , therefore consider agent acceptable alternative cidofovir , give absence clear first line option . BK virus infection define presence BK virus positivity detect PCR culture one site blood urine . BK virus disease define presence BK virus detectable culture PCR blood urine body fluid symptom disease include , limited persistent microscopic macroscopic hematuria detectable BK virus one site . Failure therapy define rise fall le 50 % viral load peripheral blood site disease measure PCR quantitative assay ) worsen hematuria 7 day antiviral therapy . 5 . HHV6 : Treatment persistent HHV6 infection disease despite antiviral treatment ganciclovir , cidofovir foscarnet . No clear standard treatment define . Ganciclovir , cidofovir foscarnet variable vitro activity HHV6 , may role treat HHV6associated disease therefore antiviral treatment one agents acceptable initial therapy . HHV6 virus infection define presence elevate HHV6 level detect PCR positive culture one site CSF blood . HHV6 disease define define presence HHV6 detectable culture PCR one sit blood CSF symptom disease include symptom HHV6 encephalitis OR detectable HHV6 PCR culture one site . Failure therapy define rise fall le 50 % viral load peripheral blood site disease ( measure PCR quantitative assay ) 7 day antiviral therapy . 6 . JC virus : Treatment progressive persistent JC virus infection disease without suitable alternative treatment option . Pepmixes specific antigen adenovirus , EBV , CMV , HHV6 BK virus use generate multivirusspecific VSTs . No pepmix specific rare JC virus use generation CTLs , however give high homology ( &gt; 90 % ) JC BK fact BK virusspecific T cell target VP1 Large T ( target multivirus VSTs ) administer treat JCVPML , result viral clearance cerebrospinal fluid likely VSTs efficacious JC virus . Given current lack treatment option JC virus infection reactivation HSCT risk progression JML , almost uniformly fatal , apparent activity BK virusdirected T cell JC virus infect cell , propose include patient progressive persistent JC virus study , unless suitable alternative therapy available . JC virus infection define presence elevate JC virus level detect PCR positive culture one site CSF blood . JC virus disease define define presence JC virus detectable culture PCR one sit blood CSF symptom disease include symptom PML OR detectable JC virus PCR culture one site . 3 . Patients multiple CMV , EBV , Adenovirus , HHV6 BK virus infection eligible give infection persistent despite standard therapy define . Patients multiple infection one reactivation one control infection eligible enroll . 4 . Clinical status enrollment allow taper steroid equal less 0.5 mg/kg/day prednisone ( equivalent ) . 5 . HgB &gt; 8.0 6 . Pulse oximetry &gt; 90 % room air 7 . Available multivirusspecific VSTs 8 . Negative pregnancy test female patient applicable ( childbearing potential receive reduced intensity condition regimen ) . 9 . Written inform consent and/or sign assent line patient , parent guardian . 1 . Patients receive ATG , Campath immunosuppressive T cell monoclonal antibody within 28 day screen enrollment . 2 . Patients uncontrolled infection . For bacterial infection , patient must receive definitive therapy sign progress infection 72 hour prior enrollment . For fungal infection patient must receive definitive systemic antifungal therapy sign progress infection 1 week prior enrollment . Progressing infection define hemodynamic instability attributable sepsis new symptom , worsen physical sign radiographic finding attributable infection . Persisting fever without sign symptom interpret progress infection . 3 . Patients less 28 day remove allogeneic hematopoieteic stem cell transplant receive donor lymphocyte infusion ( DLI ) within 28 day . 4 . Patients active acute GVHD grade IIIV . 5 . Active uncontrolled relapse malignancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CMV infection</keyword>
	<keyword>EBV infection</keyword>
	<keyword>HHV6 virus infection</keyword>
	<keyword>BK virus infection</keyword>
	<keyword>Adenovirus infection</keyword>
	<keyword>JC virus infection</keyword>
	<keyword>allogeneic stem cell transplant</keyword>
	<keyword>Virus Specific T cell</keyword>
</DOC>